The levels of circulating long non-coding RNA GAS5 in prostate cancer patients: A single-center study
Background/Aim. Prostate carcinoma (PCa) is second occurring carcinoma that affects the male population. Although PCa incidence rates are high, most cases have a favorable prognosis, with comfortable long-term life quality. The aim of the study was to compare long non-coding RNA (lncRNA) growth arre...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Military Health Department, Ministry of Defance, Serbia
2023-01-01
|
| Series: | Vojnosanitetski Pregled |
| Subjects: | |
| Online Access: | https://doiserbia.nb.rs/img/doi/0042-8450/2023/0042-84502200075M.pdf |
| _version_ | 1797807497965207552 |
|---|---|
| author | Mišović Miroslav Aleksić Predrag Kostić Dejan Vuković Miodrag Radojičić Bojan Rančić Nemanja Cikota-Aleksić Bojana |
| author_facet | Mišović Miroslav Aleksić Predrag Kostić Dejan Vuković Miodrag Radojičić Bojan Rančić Nemanja Cikota-Aleksić Bojana |
| author_sort | Mišović Miroslav |
| collection | DOAJ |
| description | Background/Aim. Prostate carcinoma (PCa) is second occurring carcinoma that affects the male population. Although PCa incidence rates are high, most cases have a favorable prognosis, with comfortable long-term life quality. The aim of the study was to compare long non-coding RNA (lncRNA) growth arrest-specific transcript 5 (GAS5) plasma levels between healthy individuals and patients with PCa, and also between PCa patients with different prognostic scores. Methods. The present study included a total of 40 patients with PCa and a control group of 20 healthy individuals. PCa patients were divided into two subgroups (20 patients each) based on the prognostic criteria of the American Joint Committee on Cancer. The patient data were collected and analyzed; lncRNA GAS5 levels were quantified using the re-al-time polymerase chain reaction method. Statistical analysis was conducted using the IBM SPSS Statistics 26.0 computer program (IBM, USA, 2019). Results. The relative quantification of lncRNA GAS5 expression levels showed down-regulation in PCa patients compared to healthy individuals; however, the difference was marginally statistically significant (p = 0.056). With further analysis of the given results, we concluded that the expression level of lncRNA GAS5 was not significantly different in the first patient subgroup and the healthy individuals (p = 0.268). Patients from the second subgroup had significantly lower plasma levels of lncRNA GAS5 than healthy individuals (p = 0.033). The difference in the level of lncRNA GAS5 expression between patients with favorable prognoses (Group 1) and the ones with worse prognostic scores (Group 2) did not indicate statistical significance (p = 0.275). In both Group 1 (p = 0.805) and Group 2 (p = 0.454), the plasma levels of lncRNA GAS5 were not significantly different in comparison to the age (≤ 65 vs. > 65 years). Conclusion. One of the main objectives of PCa research is identifying novel and more efficient biomarkers. Conducted research provides strong evidence about the significance of lncRNAs GAS5 in PCa, as well as the correlation between decreased expression of lncRNA GAS5 and poor prognosis in various tumors. |
| first_indexed | 2024-03-13T06:23:24Z |
| format | Article |
| id | doaj.art-193fb993787a49bf8e76d2fb9a7147ec |
| institution | Directory Open Access Journal |
| issn | 0042-8450 2406-0720 |
| language | English |
| last_indexed | 2024-03-13T06:23:24Z |
| publishDate | 2023-01-01 |
| publisher | Military Health Department, Ministry of Defance, Serbia |
| record_format | Article |
| series | Vojnosanitetski Pregled |
| spelling | doaj.art-193fb993787a49bf8e76d2fb9a7147ec2023-06-09T10:45:02ZengMilitary Health Department, Ministry of Defance, SerbiaVojnosanitetski Pregled0042-84502406-07202023-01-0180540441110.2298/VSP220412075M0042-84502200075MThe levels of circulating long non-coding RNA GAS5 in prostate cancer patients: A single-center studyMišović Miroslav0https://orcid.org/0000-0002-4803-3341Aleksić Predrag1Kostić Dejan2https://orcid.org/0000-0002-4420-6348Vuković Miodrag3Radojičić Bojan4https://orcid.org/0000-0001-8230-6473Rančić Nemanja5https://orcid.org/0000-0002-5122-8094Cikota-Aleksić Bojana6https://orcid.org/0000-0002-9998-3996Military Medical Academy, Institute of Radiology, Belgrade, Serbia + University of Defence, Faculty of Medicine of the Military Medical Academy, Belgrade, SerbiaUniversity of Defence, Faculty of Medicine of the Military Medical Academy, Belgrade, Serbia + Military Medical Academy, Clinic for Urology, Belgrade, SerbiaMilitary Medical Academy, Institute of Radiology, Belgrade, Serbia + University of Defence, Faculty of Medicine of the Military Medical Academy, Belgrade, SerbiaUniversity of Belgrade, Faculty of Biology, Belgrade, SerbiaCenter for Military Medical Institutions, Department of Radiology, Belgrade, SerbiaUniversity of Defence, Faculty of Medicine of the Military Medical Academy, Belgrade, Serbia + Military Medical Academy, Center for Clinical Pharmacology, Belgrade, SerbiaMilitary Medical Academy, Center for Clinical Pharmacology, Belgrade, SerbiaBackground/Aim. Prostate carcinoma (PCa) is second occurring carcinoma that affects the male population. Although PCa incidence rates are high, most cases have a favorable prognosis, with comfortable long-term life quality. The aim of the study was to compare long non-coding RNA (lncRNA) growth arrest-specific transcript 5 (GAS5) plasma levels between healthy individuals and patients with PCa, and also between PCa patients with different prognostic scores. Methods. The present study included a total of 40 patients with PCa and a control group of 20 healthy individuals. PCa patients were divided into two subgroups (20 patients each) based on the prognostic criteria of the American Joint Committee on Cancer. The patient data were collected and analyzed; lncRNA GAS5 levels were quantified using the re-al-time polymerase chain reaction method. Statistical analysis was conducted using the IBM SPSS Statistics 26.0 computer program (IBM, USA, 2019). Results. The relative quantification of lncRNA GAS5 expression levels showed down-regulation in PCa patients compared to healthy individuals; however, the difference was marginally statistically significant (p = 0.056). With further analysis of the given results, we concluded that the expression level of lncRNA GAS5 was not significantly different in the first patient subgroup and the healthy individuals (p = 0.268). Patients from the second subgroup had significantly lower plasma levels of lncRNA GAS5 than healthy individuals (p = 0.033). The difference in the level of lncRNA GAS5 expression between patients with favorable prognoses (Group 1) and the ones with worse prognostic scores (Group 2) did not indicate statistical significance (p = 0.275). In both Group 1 (p = 0.805) and Group 2 (p = 0.454), the plasma levels of lncRNA GAS5 were not significantly different in comparison to the age (≤ 65 vs. > 65 years). Conclusion. One of the main objectives of PCa research is identifying novel and more efficient biomarkers. Conducted research provides strong evidence about the significance of lncRNAs GAS5 in PCa, as well as the correlation between decreased expression of lncRNA GAS5 and poor prognosis in various tumors.https://doiserbia.nb.rs/img/doi/0042-8450/2023/0042-84502200075M.pdfbiomarkersprognosisprostate neoplasmsrna, long noncoding |
| spellingShingle | Mišović Miroslav Aleksić Predrag Kostić Dejan Vuković Miodrag Radojičić Bojan Rančić Nemanja Cikota-Aleksić Bojana The levels of circulating long non-coding RNA GAS5 in prostate cancer patients: A single-center study Vojnosanitetski Pregled biomarkers prognosis prostate neoplasms rna, long noncoding |
| title | The levels of circulating long non-coding RNA GAS5 in prostate cancer patients: A single-center study |
| title_full | The levels of circulating long non-coding RNA GAS5 in prostate cancer patients: A single-center study |
| title_fullStr | The levels of circulating long non-coding RNA GAS5 in prostate cancer patients: A single-center study |
| title_full_unstemmed | The levels of circulating long non-coding RNA GAS5 in prostate cancer patients: A single-center study |
| title_short | The levels of circulating long non-coding RNA GAS5 in prostate cancer patients: A single-center study |
| title_sort | levels of circulating long non coding rna gas5 in prostate cancer patients a single center study |
| topic | biomarkers prognosis prostate neoplasms rna, long noncoding |
| url | https://doiserbia.nb.rs/img/doi/0042-8450/2023/0042-84502200075M.pdf |
| work_keys_str_mv | AT misovicmiroslav thelevelsofcirculatinglongnoncodingrnagas5inprostatecancerpatientsasinglecenterstudy AT aleksicpredrag thelevelsofcirculatinglongnoncodingrnagas5inprostatecancerpatientsasinglecenterstudy AT kosticdejan thelevelsofcirculatinglongnoncodingrnagas5inprostatecancerpatientsasinglecenterstudy AT vukovicmiodrag thelevelsofcirculatinglongnoncodingrnagas5inprostatecancerpatientsasinglecenterstudy AT radojicicbojan thelevelsofcirculatinglongnoncodingrnagas5inprostatecancerpatientsasinglecenterstudy AT rancicnemanja thelevelsofcirculatinglongnoncodingrnagas5inprostatecancerpatientsasinglecenterstudy AT cikotaaleksicbojana thelevelsofcirculatinglongnoncodingrnagas5inprostatecancerpatientsasinglecenterstudy AT misovicmiroslav levelsofcirculatinglongnoncodingrnagas5inprostatecancerpatientsasinglecenterstudy AT aleksicpredrag levelsofcirculatinglongnoncodingrnagas5inprostatecancerpatientsasinglecenterstudy AT kosticdejan levelsofcirculatinglongnoncodingrnagas5inprostatecancerpatientsasinglecenterstudy AT vukovicmiodrag levelsofcirculatinglongnoncodingrnagas5inprostatecancerpatientsasinglecenterstudy AT radojicicbojan levelsofcirculatinglongnoncodingrnagas5inprostatecancerpatientsasinglecenterstudy AT rancicnemanja levelsofcirculatinglongnoncodingrnagas5inprostatecancerpatientsasinglecenterstudy AT cikotaaleksicbojana levelsofcirculatinglongnoncodingrnagas5inprostatecancerpatientsasinglecenterstudy |